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Summary 
 
 One hundred thirteen Hereford x Angus 
heifer calves (average weight = 515 lb) were 
allotted to one of three treatments: 1) control, 
no vaccine; 2) a 2-cc subcutaneous injection 
of One-Shot® (Pfizer Animal Health), a 
Mannheimia (pasteurella) haemolytica vac-
cine, three weeks before weaning; or 3) a ½-cc 
intradermal injection of One-Shot, three 
weeks before weaning.  All heifers were 
weighed and blood samples harvested at time 
of injection, three weeks later at weaning, and 
then 28 days later.  After weaning, heifers 
were confined to a common pen and fed free-
choice brome hay and approximately 5 
lb/head daily of a concentrate.  Blood samples 
from 30 heifers were shipped to a laboratory 
for titer analysis.  No differences were found 
in animal performance and sickness during the 
preconditioning period.  Heifers injected by 
the subcutaneous route had greater increases 
in whole-cell and leukotoxin-neutralizing an-
tibody titer levels than the intradermal or con-
trol treatments.  These data suggest that beef 
producers should follow label recommenda-
tions for dosage and route of administration to 
maximize vaccine efficacy. 
 
Introduction 
 
 Mannheimia haemolytica is the major bac-
terium responsible for severe disease (bovine 
respiratory disease) and economic losses in 
cattle.  Research has indicated that weanling 
calves vaccinated subcutaneously for M. 
haemolytica with One-Shot® (Pfizer Animal 
Health) responded with a significant increase 
in whole-cell and leukotoxin-neutralizing an-
tibody titers. Increasing titers would indicate 
that the animal’s immune system reacted to 
the vaccine and is better prepared to defend 
the body against disease challenges. This 
study was conducted to determine if use of an 
intradermal route of administration with a 
smaller dosage would elevate antibody titers 
and have the potential to reduce morbidity and 
increase performance in cattle.  
 
Experimental Procedures 
 
 One hundred thirteen Hereford x Angus, 
spring-born heifers were randomly assigned to 
treatments three weeks before weaning (Sep-
tember 24, 2002).  Heifers were weighed, and 
blood samples were harvested before vaccina-
tion and were properly stored.  Heifers were 
then processed with FORTRESS 7® (Pfizer 
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Animal Health) and CATTLEMASTER 4® 
(Pfizer Animal Health). According to treat-
ment assignment, heifers received one of three 
injection treatments of a M. haemolytica vac-
cine (One-Shot®, Pfizer Animal Health): 1) 
control, no vaccine administered; 2) a 2-cc 
subcutaneous injection of the M. haemolytica 
vaccine; or 3) a ½-cc intradermal injection of 
the M. haemolytica vaccine.  Twenty-one days 
later (October 14), heifers were again weighed 
and blood samples taken and properly stored.  
Samples from both sampling days were for-
warded to Oklahoma State University for 
whole-cell and leukotoxin-neutralizing anti-
body analysis.  Two blood samples were not 
analyzed. All injections were given in the 
calves’ neck region, following standard KSU/ 
KVMA/KLA Beef Quality Assurance guide-
lines. 
 
Results and Discussion 
 
 The initial weight of heifers treated in-
tradermally was less than heifers in other 
treatments, but initial weight had no effect on 
gain or blood-work results (Table 1).  Weight 
gains and morbidity were similar between 
treatments.  No differences in basal titer levels 
were noted between treatments groups (Table 
2).  Changes in whole-cell titer in response to 
vaccination were not different among treat-
ments (P>0.55).  However, the leukotoxin-
neutralizing antibody tests indicated that the 
subcutaneous treatment resulted in a greater 
increase in antibody concentration than either 
the control (P=0.004) or intradermal (P=0.21) 
treatments.   
 
 These heifers were neither transported nor 
commingled with externally sourced cattle 
during this trial.  Health records reflected this 
management program, in as much as no heif-
ers were treated for bovine respiratory disease 
or died during the preconditioning period. 
 
 One-Shot vaccine was effective in increas-
ing the leukotoxin-neutralizing antibody titer 
levels in weaning-age calves, whereas whole-
cell titers were less responsive. The recom-
mended route of administration and dosage 
seems to give best results. 
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Table 1.  Effects of Volume and Route of Administration of a Mannheimia haemolytica 
Vaccine (One-Shot®, Pfizer Animal Health) on Animal Performance 
 
Item: 
Control/ 
No Vaccine 
2 cc 
Subcutaneous
½ cc 
Intradermal 
 
SEM 
Initial weight, lb 512a 521a 500b 6.2 
Average daily gain, lb/day 
September 24 to October 15 1.6 1.7 1.7 0.12 
October 15 to November 12 1.3 1.4 1.2 0.10 
September 24 to November 12 1.5 1.5 1.5 0.04 
abMeans with different superscripts within row differ (P<0.05). 
 
 
 
 
Table 2.  Effects of Volume and Route of Administration of a Mannheimia haemolytica 
Vaccine (One-Shot®, Pfizer Animal Health) on Serological Test Results 
Item: 
Control/ 
No Vaccine 
2 cc 
Subcutaneous 
½ cc 
Intradermal SEM 
Titer level, September 24 
Whole cell 0.28 0.32 0.43 0.11 
LktNA* 0.16 0.18 0.15 0.050 
 
Titer level, October 14 
Whole cell 0.37 0.64 0.54 0.12 
LktNA* 0.22a 0.48b 0.33a 0.063 
 
Change in titer level, September 24 to October 14 
Whole cell 0.04 0.30 0.21 0.12 
LktNA* 0.05a 0.33b 0.17a 0.069 
*Leukotoxin-neutralizing antibody. 
abMeans with different superscripts within row differ (P<0.10). 
